[
  {
    "ts": null,
    "headline": "How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story",
    "summary": "Analysts covering AbbVie have been fine tuning their models, with fair value per share adjusted slightly from US$245.22 to US$244.96 and the discount rate moved from 7.38% to 7.36%, reflecting only small shifts in how risk and long term growth are being weighed. These changes align with a broader mix of optimism and caution regarding how much future drug growth is already in the price and how competition and pipeline progress could affect the story over time. Stay with this article to see how...",
    "url": "https://finnhub.io/api/news?id=0f3ba7aef7c6c857b593f111c79fbe0d76c9f8b2c3bb2afa3c6fe52fe4fd9329",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770667695,
      "headline": "How Recent Analyst Shifts Are Reframing AbbVie (ABBV) And Its Valuation Story",
      "id": 138789758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Analysts covering AbbVie have been fine tuning their models, with fair value per share adjusted slightly from US$245.22 to US$244.96 and the discount rate moved from 7.38% to 7.36%, reflecting only small shifts in how risk and long term growth are being weighed. These changes align with a broader mix of optimism and caution regarding how much future drug growth is already in the price and how competition and pipeline progress could affect the story over time. Stay with this article to see how...",
      "url": "https://finnhub.io/api/news?id=0f3ba7aef7c6c857b593f111c79fbe0d76c9f8b2c3bb2afa3c6fe52fe4fd9329"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770655080,
      "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
      "id": 138693763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=41405dd86b09ed0279733ecbeca2fcb29dcd59a3254409eb2027a4744c51d62a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss",
    "summary": "JNJ's Innovative Medicine unit grew sales 4.1% in 2025 despite Stelara'sZER LOE, topping $60B as Darzalex and new drugs offset pressure",
    "url": "https://finnhub.io/api/news?id=607347dec3f1bbb23856464cc50ee4d2270338b62616b19102569ae87a2c96a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770647040,
      "headline": "J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss",
      "id": 138608841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine unit grew sales 4.1% in 2025 despite Stelara'sZER LOE, topping $60B as Darzalex and new drugs offset pressure",
      "url": "https://finnhub.io/api/news?id=607347dec3f1bbb23856464cc50ee4d2270338b62616b19102569ae87a2c96a0"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
    "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
    "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770646260,
      "headline": "Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?",
      "id": 138514556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.",
      "url": "https://finnhub.io/api/news?id=6218bf24bf276aa438d0322878a67902e49fbb755d6b459d5558db730538d5d7"
    }
  },
  {
    "ts": null,
    "headline": "3 Market-Beating Stocks to Research Further",
    "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
    "url": "https://finnhub.io/api/news?id=e019025a244b02fb0bdd8c52c95ca14b6a824fe18dd89c236ce3a4a798e90812",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770612115,
      "headline": "3 Market-Beating Stocks to Research Further",
      "id": 138400490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
      "url": "https://finnhub.io/api/news?id=e019025a244b02fb0bdd8c52c95ca14b6a824fe18dd89c236ce3a4a798e90812"
    }
  }
]